Abstract

The target of treatment for rheumatoid arthritis (RA) is to keep low disease activity or remission. Tocilizumab can fully inhibit interleukin-6 and C reactive protein (CRP) production. The goal of...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Value of anti-mutated citrullinated vimentin antibody and anti-cyclic citrullinated peptide antibody in the prediction of bone erosion and disease activity of rheumatoid arthritis
...
-
, et. al. ...
15 Jan 2017
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
Arthur Kavanaugh ... Jennifer Green
The Lancet | VOL. 381
Arthur Kavanaugh, et. al.Arthur Kavanaugh ... Jennifer Green
18 Mar 2013
THU0064 ADAM-10 as a tocilizumab treatment predictive factor in rheumatoid arthritis
A Nishimi ... T Kasama
Annals of the Rheumatic Diseases | VOL. 76
A Nishimi, et. al.A Nishimi ... T Kasama
01 Jun 2017
SAT0262 Comparison of Serum Matrix Metalloproteinase-3 Levels in Rheumatoid Arthritis after Treatment with Biologic Agents for 24 Weeks
...
Annals of the Rheumatic Diseases | VOL. 73
, et. al. ...
01 Jun 2014
View more papers

More From: Journal of Investigative Medicine

Paper Title
Journal
Date
Author
Current status of novel weight loss interventions
Nabil Tariq ... Aman B Ali
Journal of Investigative Medicine | VOL. 72
Nabil Tariq, et. al.Nabil Tariq ... Aman B Ali
24 May 2024
2023 AFMR National Meeting
-
Journal of Investigative Medicine | VOL. 72
--
13 Dec 2023
2024 Western Medical Research Conference
-
Journal of Investigative Medicine | VOL. 72
--
13 Dec 2023
Midwest Clinical & Translational Research Meeting Supplement
-
Journal of Investigative Medicine | VOL. 71
--
01 Oct 2023
View more papers